# vTv Therapeutics

Organization · id `cardio:org-vtv-therapeutics` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=vTv+Therapeutics>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 4 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: vTv Therapeutics
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes (`cardio:ct-nct01474083`)
- Sponsors: A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes (`cardio:ct-nct01665352`)
- Sponsors: Add Glucokinase Activator to Target A1c (`cardio:ct-nct02405260`)
- Sponsors: A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes (`cardio:ct-nct02653599`)

## Provenance

Content hash: 543bda03d8d4441d5a1d5521969af0508feed26c85c4889548d8cb171bb276a6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
